Stone Paul A.
Known title: SVP, Chief Financial OfficerCIK: 0001777511
Associated companies
Transaction History
| IDYA | ▼ Sell | Open Market | 5,000 | $144K | 8/29/2023 | View on chart |
| IDYA | ▼ Sell | Open Market | 978 | $26K | 8/21/2023 | View on chart |
| IDYA | ▼ Sell | Open Market | 3,822 | $101K | 8/18/2023 | View on chart |
| IDYA | ▼ Sell | Open Market | 100 | $3K | 8/16/2023 | View on chart |
| IDYA | ▼ Sell | Open Market | 100 | $3K | 8/16/2023 | View on chart |
| IDYA | ▼ Sell | Open Market | 2,500 | $63K | 8/9/2023 | View on chart |
| IDYA | ▲ Buy | Option Exercise | 8,000 | $37K | 4/13/2023 | View on chart |
| IDYA | ▼ Sell | Open Market | 2,500 | $69K | 9/7/2021 | View on chart |
| IDYA | ▲ Buy | Grant | 859 | $10K | 5/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
IDEAYA Biosciences Rethinks R&D Leadership Amid Valuation Questions
IDEAYA Biosciences is reevaluating its research and development leadership structure as questions about the company's valuation grow. This internal restructuring occurs while the stock trades near its support level of $35.91, well below the average analyst target of $52.75. The move signals a strategic shift in how the company approaches its scientific pipeline and cost management.
IDEAYA Biosciences Rethinks R&D Leadership Amid Valuation Questions. IDEAYA Biosciences is reevaluating its research and development leadership structure as questions about the company's valuation grow. This internal restructuring occurs while the stock trades near its support level of $35.91, well below the average analyst target of $52.75. The move signals a strategic shift in how the company approaches its scientific pipeline and cost management.